



8th AltUN Annual Meeting

Medicines for Children's safe: challenges and opportunities

Pavia, Italy•6–7 March 2014

Abstract Form

Presenting Author Info

Title (PhD, PhD Student, Student...) Student

First name LAURA

Last name DEL MARCO

Company/University FARMACIA SEGURO

Address VIA EDISON 5

Postal Code 20019

City SETTIMO MILANESE (MI)

Country ITALY

e-mail laura.delmarco@hotmail.it

Telephone No 3395289342

**Do you agree with publishing the abstract
on AltUN website (www.aitun.it)?**

YES

INSTRUCTION FOR SUBMISSION

The Abstract (360 words max) must be in ENGLISH

Format of Abstract: One page Only;

Font: Arial Narrow, size 12;

Margins: Top= 2.5 cm, Bottom= 2.5 cm, Left= 3 cm,

Right= 3 cm.

The Abstract should be limited to the following sections:

- Purpose
- Methods
- Results
- Conclusions

Underline initials and last name of the presenting author and indicate email. Add affiliations for each authors.

Please, send the abstract by email to info@aitun.it before **7 February, 2014**.

The best abstracts will be selected for podium presentation.

Authors will be notified of the mode of presentation (oral or poster) by **14 February, 2014**

CONTINUITY THERAPEUTIC HOSPITAL TERRITORY: PREPARATION GALENICA OF PROPRANOLOL FOR PATIENTS SUFFERING FROM SERIOUS CHILD HEMANGIOMA

^a Elisa Giubileo, ^{a,*} L. Del Marco, ^a V. Riccardi, ^a A. Bolzani, ^a S. Chisale'

^a Farmacia Territoriale, Seguro – 20019 Settimo Milanese - Milano
(Italy)

* laura.delmarco@hotmail.it

Purpose

The infantile hemangiomas are the most common soft tissue tumors of children. Local complications, such as bleeding and ulcers can be very painful. Hemangiomas present in the airways and in the liver can be life-threatening. In the medical literature have recently reported the results in favor of propranolol acting beta-blocking drug, in stopping the proliferative phase of infantile hemangiomas.

The purpose of our work is the good collaboration between specialists, pediatricians and Clinical Pharmacist in the sharing of path-diagnostic-drug of the patient, to ensure the continuity therapeutic hospital-territory through the preparation of pharmaceutical preparations not otherwise available in pediatric trade.

Methods

We have analyzed the requirements of propranolol galenic received at our pharmacy within the last 12 months.

From here the development of our work which included the following steps:

Step 1: "Analysis of the requirements and extrapolation of the recipes related to possible indication" severe hemangioma "

Step 2: "review of the literature".

Step 3: "Contact with the Center Prescriber.

Results

In this period, they have turned to our Pharmacy parents of 10 patients from 2 different centers prescribers. (A.O. ICP Milan - AO Buzzi of Milan) .The age of the patient at the time of initiation of therapy ranged from 3 months to two years. The starting dose of propranolol was between 1.5 mg / kg / day and 3 mg / kg / day.

The pharmaceutical form choice was: capsules with lactose excipient, which once opened are dissolved easily in foods for infants.

The physiological weight gain of children is correlated with the need to change the single dose, often bringing the patient to the pharmacy.

Through contacts with prescribers centers, it was possible to collect data on the evolution of clinical cases treated, that although preliminary consent to affirm the benefits of therapy.

Conclusions

Propranolol administered orally in doses of 1.5 / 3 mg / kg per day showed a rapid therapeutic effect with significant shortening of the natural course of infantile hemangioma, with a good clinical tolerance.

The prescription drug prescribed for pediatric patients can be a problem as they often do not exist in neither trade nor dosage formulations suitable. The preparation magistral then assumes a decisive role to ensure the appropriate therapy.